Nov. 30 at 12:02 AM
$KZIA 10 FDA Clinical trials have already been conducted with pAX in monotherapy. Over the past 7 years Harvard, Dana Farber, Memorial Sloan, John Hopkins, UCLA & St Jude children's sought out pAX to conduct various brain cancer studies. Additionally, pAX was selected for major international trials - GBM AGILE and a children brain group, PNOC. The float size ran up to A
$200M. Paxalisib successfully inhibited the damaged PI3K pathway, but subsequently, it has been learnt that cancer uses alternatives pathways in the human body, to grown itself. (If the FDA accepts what is known now, that combination drugs, supercharges pAX, then approval will quickly be forthcoming). Fast forward & without that recent science from QIMR,
$CELC , secured a PI3K mTOR drug called gedatolisib and in 2022, commenced combination drug studies. Celcuity a
$5 b company now, but gedatolisib is non CNS effective. All this serves to highlight the vast potential of pAX & acknowledgment of collaborator QIMR.
